Medicis ships Restylane, Perlane after FDA nod
The Food and Drug Administration (FDA) on Jan. 29 approved Restylane-L for implantation into the mid- to deep dermis and Perlane-L for implantation into the deep dermis to superficial subcutis. Both fillers are intended for the correction of moderate to severe facial wrinkles, such as nasolabial folds.
GlobeNewswire quotes Medicis Chairman and CEO Jonah Shacknai as saying, “We are pleased to be shipping Restylane-L and Perlane-L just two weeks after announcing FDA approval. Restylane is the first and only hyaluronic acid dermal filler approved to last up to 18 months with one repeat treatment. We believe the addition of 0.3 percent lidocaine to Restylane ... and Perlane is an offering physicians and their patients will appreciate.”
MORE ARTICLES IN THIS ISSUE
Wayland, Mass. — Candela Corp., a Syneron company based here, announced Feb. 10 that China's State Food and Drug Administration (SFDA) has approved Candela's Alex TriVantage multi-wavelength laser system and the GentleMax multiple wavelength workstation for sale throughout the People's Republic of China.
National report — The 7.3 earthquake that decimated Haiti's capital of Port-au-Prince in January also leveled sites where U.S. dermatologists have been focusing training and aid efforts since 2003, according to the American Academy of Dermatology (AAD).
Exeter, N.H. — Seacoast Pathology, based here, has launched its new DermDX division, which features a state-of-the-art on-site laboratory to service New England-area dermatologists and their patients.
Bridgewater, N.J. — Recently released results of a new study suggest that treatment with Sculptra Aesthetic (poly-L-lactic acid, Sanofi-Aventis) is significantly more effective than the human-derived collagen treatment CosmoPlast (Allergan) in correcting shallow to deep nasolabial folds, PR Newswire reports.
Wellington, New Zealand — The Food and Drug Administration (FDA) has granted 510(k) clearance for Endoform Dermal Template, an extracellular matrix biomaterial manufactured by New Zealand regenerative medicine company Mesynthes.